NK-cell therapy in resistant MDS, AML

Print Friendly, PDF & Email


Natural killer cell
destroying a cancer cell
Image by Joshua Stokes
Results of a phase 1/2 trial suggest treatment with haploidentical natural killer (NK) cells can be effective against relapsed/refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). NK-cell therapy elicited responses in 6 of the 16 patients studied and provided a bridge... [Read Article]
Print Friendly, PDF & Email

Young kids with SCA not receiving recommended prophylaxis

Print Friendly, PDF & Email


Doctor examines
sickle cell patient
Photo from St. Jude
Children’s Research Hospital
Many young children with sickle cell anemia (SCA) may not be taking the recommended antibiotics to prevent invasive pneumococcal disease (IPD), according to research published in Pediatrics. Results of a previous study indicated that daily treatment with penicillin could reduce the... [Read Article]
Print Friendly, PDF & Email

Azacitidine now available in China

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with intermediate-2/high-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) with 20% to 30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). Azacitidine for injection is marketed in... [Read Article]
Print Friendly, PDF & Email

Predicting response to AZA in MDS, CMML

Print Friendly, PDF & Email


Micrograph showing MDS
Researchers have developed a technique that may help predict whether patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) will respond to treatment with azacytidine (AZA). “The new method, called AZA-MS, utilizes a cutting-edge technique known as mass spectrometry to measure the different forms of AZA inside blood cells... [Read Article]
Print Friendly, PDF & Email

Caplacizumab improves outcomes in aTTP

Print Friendly, PDF & Email


Marie Scully, MD
Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at the 2017 ASH Annual Meeting. In the phase 3 HERCULES trial, researchers compared caplacizumab, an anti-von Willebrand factor nanobody, plus standard care (plasma exchange and immunosuppression) to placebo plus standard care in patients... [Read Article]
Print Friendly, PDF & Email

Drug granted breakthrough status as first-line SAA therapy

Print Friendly, PDF & Email


Eltrombopag (Promacta)
Photo courtesy of GSK
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to eltrombopag (Promacta®) for use in combination with standard immunosuppressive therapy as first-line treatment for patients with severe aplastic anemia (SAA). Novartis plans to submit an application to the FDA for this indication later this year.... [Read Article]
Print Friendly, PDF & Email